Loading...
•
Sep 30, 2022
Tectonic Q3 2022 Earnings Report
AVROBIO reported a net loss for Q3 2022, driven by a reduction in research and development expenses. The company highlighted progress in its gene therapy programs, including rare pediatric disease designations for Gaucher disease and cystinosis.
Key Takeaways
AVROBIO reported a net loss of $23.0 million for the third quarter of 2022, compared to a net loss of $32.6 million for the same period in 2021. The decrease was attributed to a reduction in research and development expenses. The company's cash and cash equivalents as of September 30, 2022, are expected to fund operating expenses and capital expenditure requirements into the first quarter of 2024.
Patient dosing was completed in a collaborator-sponsored Phase 1/2 clinical trial for cystinosis.
Rare pediatric disease designations were received for Gaucher disease and cystinosis investigational gene therapies.
A comprehensive Gaucher disease program update is planned for December 7.
A clinical trial application for Hunter syndrome was approved by MHRA.